Rekürren Laringeal Papillomatoziste Güncel Tedavi ve Yönetim

Yıl 2021, Cilt: 4 Sayı: 2, 131 - 137, 31.08.2021

Elvan Onan

Öz

Özet: Laringeal papillomlar, solunum yolunun farklı yerlerinde epitel hücrelerinde aşırı büyümeye neden olan viral bir enfeksiyonun neden olduğu iyi huylu bir lezyondur. Etken Human Papilloma virüsüdür. Standart tedavi yöntemi lezyonların cerrahi olarak eksizyonudur. lazer, mikrodebrider, soğuk cerrahi aletler veya bunların kombinasyonu kullanılarak genel anestezi altında operasyon gerçekleştirilir. Cerrahi tedavi ile kontrol altına alınamayan olgularda adjuvan tedavi seçenekleri planlanır.


Abstract: Recurrent laryngeal papillomas are the benign lesion caused by a viral infection with overgrowth of epithelial cells in different parts of the respiratory tract. It is caused by the human papillomavirus. Standard treatment method is surgical excision of the lesions. Laser, microdebrider, cold surgical instruments or combinations can be used in operation under general anesthesia. Adjuvant treatment options are planned in cases that cannot be controlled by surgical treatment.

Anahtar Kelimeler

rekürren laringeal papillomatozis, sidofovir, human papilloma virüs

Kaynakça

• 1. Abramson AL, Steinberg BM, Winkler B. Laryngeal papillomatosis: clinical, histopathologic and molecular studies. Laryngoscope 1987;97:678–685
• 2. Rabah R, Lancaster WD, Thomas R, Gregoire L. Human papillomavirus11-associated recurrent respiratory papillomatosis is more aggressive than human papillomavirus-6-associated disease. Pediatr Dev Pathol 2001;4:68–72.
• 3. Nebesio CL, Mirowski GW, Chuang TY. Human papillomavirus: clinical significance and malignant potential. Int J Dermatol 2001;40:373– 379.
• 4. Silverberg MJ, Thorsen P, Lindeberg H, Ahdieh-Grant L, Shah KV. Clinical course of recurrent respiratory papillomatosis in danish children. Arch Otolaryngol Head Neck Surg 2004;130(6):711–716
• 5. Siegel B, Smith LP. Management of complex glottic stenosis in children with recurrent respiratory papillomatosis. Int J Pediatr Otorhinolaryngol 2013;77:1729–1733.
• 6. Ivancic R, Iqbal H, deSilva B, Pan O, Matrka L. Current and future management of recurrent respiratory papillomatosis. Laryngoscope Investig Otolaryngol 2018;14:22-34.
• 7. Xu W, Han D, Hou L, Zhang L, Yu Z, Huang Z. Voice function following CO2 laser microsurgery for precancerous and early-stage glottic carcinoma. Acta Otolaryngol 2007;127(6):637–641.
• 8. Yan Y, Olszewski AE, Hoffman MR. Use of lasers in laryngeal surgery. J Voice 2010;24(1):102–109.
• 9. Coulombeau B, Nusa Naiman A, Ceruse P, Froehlich P. [Anti-viral injectable treatment (cidofovir) in laryngeal papillomatosis]. Rev Laryngol Otol Rhinol (Bord) 2002;123(5):315–320
• 10. Naiman AN, Ayari S, Nicollas R, Landry G, Colombeau B, Froehlich P. Intermediate-term and long-term results after treatment by cidofovir and excision in juvenile laryngeal papillomatosis. Ann Otol Rhinol Laryngol 2006;115(9):667–672.
• 11. Gazia F, Gallett B, Freni F, Bruno R, Sireci F, Galletti C, Meduri A, Galletti F. Use of intralesional cidofovir in the recurrent respiratory papillomatosis: a review of the literatüre. Eur Rev Med Pharmacol Sci. 2020;24(2):956-62.
• 12. Grasso M, Remacle M, Bachy V, Van Der Vorst S, Lawson G. Use of cidofovir in HPV patients with recurrent respiratory papillomatosis. Eur Arch Otorhinolaryngol 2014; 271: 2983-2990
• 13. Rahbar R, Vargas SO, Folkman J, et al: Role of vascular endothelial growth factor-A in recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 114: 289-295, 2005.
• 14. Nagel S, Busch C, Blankenburg T and Schütte W: Treatment of respiratory papillomatosis - a case report on systemic treatment with bevacizumab. Pneumologie 63: 387-389, 2009
• 15. Mohr M, Schliemann C, Biermann C, et al. Rapid response to systemic bev-acizumab therapy in recurrent respiratory papillomatosis. Oncol Lett 2014;8:1912-8
• 16. Carnevale C, Cierva L, Pérez G, Zarza J, Rodriguez B, Lozano J, Echegaray P, Tagle D, Barberán M. Safe use of systemic bevacizumab for respiratory recurrent papillomatosis in two children. Laryngoscope 2019 Apr;129(4):1001-1004
• 17. Zeitels SM, Barbu AM, Landau-Zemer T, et al. Local injection of bevacizumab (Avastin) and angiolytic KTP laser treatment of recurrent respiratory papillomatosis of the vocal folds: a prospective study. Ann Otol Rhinol Laryngol. 2011;120(10):627–634
• 18. Ramet J, van Esso D, Meszner Z, European Academy of Paediatrics Scientific Working Group on Vaccination Position paper – HPV and the primary prevention of cancer: improving vaccine uptake by paediatricians. Eur J Pediatr. 2011;170(3):309–321.
• 19. Wu R, Abramson AL, Shikowitz MJ, Dannenberg AJ, Steinberg BM. Epidermal growth factor-induced cyclooxygenase-2 expression is mediated through phosphatidylinositol-3 kinase, not mitogen-activated protein/ extracellular signal-regulated kinase kinase, in recurrent respiratory papillomas. Clin Cancer Res 2005;11(17):6155–6161.
• 20. Limsukon A, Susanto I, Hoo GW, Dubinett SM, Batra RK. Regression of recurrent respiratory papillomatosis with celecoxib and erlotinib combination therapy. Chest 2009;136(3):924–926.
• 21. Makiyama K, Hirai R, Matsuzaki H. Gardasil vaccination for recurrent laryngeal papillomatosis in adult men: first report: changes in HPV antibody titer. J Voice 2017;31(1):104–106
• 22. Young DL, Moore MM, Halstead LA. The use of the quadrivalent human papillomavirus vaccine (Gardasil) as adjuvant therapy in the treatment of recurrent respiratory papilloma. J Voice. 2015;29(2):223–229.
• 23. Dion GR, Teng S, Boyd LR, et al. Adjuvant human papillomavirus vaccination for secondary prevention: a systematic review. JAMA Otolaryngol Head Neck Surg 2017;143(6):614–622